DeepMed Research

Ganciclovir

Generic Name: Ganciclovir

Brand Names: Cytovene, Zirgan

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₅O_₄

CAS Number: 82410-32-0

Unique Ingredient Identifier: P9G3CKZ4P5

Background: An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication: For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions: CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis

Clinical Trials

A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

Phase 1

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT00000668

Locations: 🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Cornell Univ Med Ctr, New York, New York, United States

and more 2 locations

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

Phase 2

Completed

Conditions: Gastrointestinal Diseases
Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 850

Registration Number: NCT00001034

Locations: 🇺🇸
Community Consortium of San Francisco, San Francisco, California, United States
🇺🇸
Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States
🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States

and more 14 locations

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

Phase 1

Completed

Conditions: HIV Infections
Cytomegalovirus Retinitis

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT00001062

Locations: 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States

and more 3 locations

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT00002034

Locations: 🇺🇸
Dr Alfred F Burnside Jr, Columbia, South Carolina, United States
🇺🇸
SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇨🇦
Southern Alberta HIV Clinic / Foothills Hosp, Calgary, Alberta, Canada

and more 6 locations

A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 225

Registration Number: NCT00002247

Locations: 🇺🇸
Mount Zion Med Ctr, San Francisco, California, United States
🇺🇸
Dr Dorothy Friedberg, New York, New York, United States
🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States

and more 17 locations

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Phase 3

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 180

Registration Number: NCT00000688

Locations: 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Stanford Univ School of Medicine, Stanford, California, United States
🇺🇸
Kansas City Veterans Administration Med Ctr, Kansas City, Missouri, United States

and more 19 locations

CMV Retinitis Retreatment Trial

Phase 2

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000766

Locations: 🇺🇸
Johns Hopkins Hosp / SOCA, Baltimore, Maryland, United States
🇺🇸
New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA, New York, New York, United States
🇺🇸
Mount Sinai Med Ctr / SOCA, New York, New York, United States

and more 6 locations

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

Phase 4

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-02-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000894

Locations: 🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸
New York Hosp / Cornell Med Ctr, New York, New York, United States

and more 9 locations

A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

Phase 3

Completed

Conditions: Cytomegalovirus Infections

First Posted Date: 2001-08-31

Last Posted Date: 2010-08-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 130

Registration Number: NCT00001100

Locations: 🇺🇸
NIAID/DMID/CASG Central Unit, Birmingham, Alabama, United States

A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

Phase 3

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-09-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000698

Locations: 🇺🇸
Natl Inst of Allergy & Infect Dis / Cln Ctr, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy